» Articles » PMID: 32251018

Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease

Abstract

Introduction: Because nonalcoholic fatty liver disease (NAFLD) is becoming a leading cause of chronic liver disease, noninvasive evaluations of its severity are immediately needed. This prospective cross-sectional study evaluated the effectiveness of noninvasive assessments of hepatic steatosis, fibrosis, and steatohepatitis.

Methods: Patients underwent laboratory tests, liver biopsy, transient elastography, and MRI. Multiparametric MR was used to measure MRI proton density fat fraction, MR spectroscopy, T1 mapping, and MR elastography (MRE).

Results: We enrolled 130 patients between October 2016 and July 2019. For the diagnosis of moderate-to-severe steatosis (grade ≥ 2), the area under the receiver operating characteristic curve (AUROC) was lower in controlled attenuation parameter (0.69; 95% confidence interval [CI], 0.60-0.76) than MRI proton density fat fraction (0.82; 95% CI, 0.75-0.89; P = 0.008) and MR spectroscopy (0.83; 95% CI, 0.75-0.89; P = 0.006). For the diagnosis of advanced fibrosis (stage ≥ 3), the AUROC of MRE (0.89; 95% CI, 0.83-0.94) was superior compared with those of the Fibrosis-4 index (0.77; 95% CI, 0.69-0.84; P = 0.010), NAFLD fibrosis score (0.81; 95% CI, 0.73-0.87; P = 0.043), and transient elastography (0.82; 95% CI, 0.74-0.88; P = 0.062). For detecting advanced fibrosis or nonalcoholic steatohepatitis, the AUROC of MRE (0.86; 95% CI, 0.79-0.91) was higher than that of TE (0.76; 95% CI, 0.68-0.83) with statistical significance (P = 0.018).

Discussion: Multiparametric MR accurately identified a severe form of NAFLD. Multiparametric MR can be a valuable noninvasive method for evaluating the severity of NAFLD.

Citing Articles

Accuracy of Non-Invasive Imaging Techniques for the Diagnosis of MASH in Patients With MASLD: A Systematic Review.

Cathcart J, Barrett R, Bowness J, Mukhopadhya A, Lynch R, Dillon J Liver Int. 2024; 45(4):e16127.

PMID: 39400428 PMC: 11891385. DOI: 10.1111/liv.16127.


Sex-specific associations in multiparametric 3 T MRI measurements in adult livers.

Liu C, Noda C, van der Geest R, Triaire B, Kassai Y, Bluemke D Abdom Radiol (NY). 2023; 48(10):3072-3078.

PMID: 37378865 DOI: 10.1007/s00261-023-03981-3.


An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.

Liang J, Ampuero J, Niu H, Imajo K, Noureddin M, Behari J J Hepatol. 2023; 79(3):592-604.

PMID: 37121437 PMC: 10623141. DOI: 10.1016/j.jhep.2023.04.025.


Reappraisal of fibrosis-4 index and non-alcoholic fatty liver disease fibrosis score for advanced fibrosis in average-risk population.

Park H, Yoon E, Kim M, Lee J, Cho S, Won Jun D Front Med (Lausanne). 2022; 9:1024836.

PMID: 36405611 PMC: 9668872. DOI: 10.3389/fmed.2022.1024836.


Non-alcoholic fatty liver disease: A patient guideline.

Francque S, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus J JHEP Rep. 2021; 3(5):100322.

PMID: 34693236 PMC: 8514420. DOI: 10.1016/j.jhepr.2021.100322.


References
1.
Grimm A, Meyer H, Nickel M, Nittka M, Raithel E, Chaudry O . Evaluation of 2-point, 3-point, and 6-point Dixon magnetic resonance imaging with flexible echo timing for muscle fat quantification. Eur J Radiol. 2018; 103:57-64. DOI: 10.1016/j.ejrad.2018.04.011. View

2.
Neuman M, Cohen L, Nanau R . Biomarkers in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol. 2015; 28(11):607-18. PMC: 4277175. DOI: 10.1155/2014/757929. View

3.
Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

4.
Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

5.
Sumida Y, Nakajima A, Itoh Y . Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014; 20(2):475-85. PMC: 3923022. DOI: 10.3748/wjg.v20.i2.475. View